about
Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer.Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migrationSynthetic and Biological Studies of Sesquiterpene Polygodial: Activity of 9-Epipolygodial against Drug-Resistant Cancer CellsAnalytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingAnchor-based classification and type-C inhibitors for tyrosine kinases.Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamicsEnhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.Personalized prediction of EGFR mutation-induced drug resistance in lung cancer.Human cancers converge at the HIF-2alpha oncogenic axis.An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.Gefitinib for non-small-cell lung cancer treatment.Suppression of epidermal growth factor receptor (EGFR) expression by small hairpin RNA inhibits the growth of human nonsmall cell lung cancers bearing wild-type and mutant EGFR.Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells.Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants.
P2860
Q24814879-4BCC2E84-754B-42DE-98F0-AD3C835E3A0AQ28829561-7E70966B-8808-4D1A-A5CE-FB9F210FDCECQ28834689-6BF564A3-2CD0-4C9D-8FE0-C48652680A54Q34690590-F95A489F-0886-4026-9956-6A4F800366FAQ35267340-2BCA131B-5C3B-44A9-BF9D-52F96EFC3DEEQ35551048-A33700FC-E39B-473D-A31D-E814C4720EAEQ35745479-24F74F15-5FB8-4942-A842-A7DE7B6134A8Q36127636-CE4928B5-9643-4B05-B808-7E39F93D3EA2Q36484536-0D6227D3-90B9-4F1D-8CD5-CC23CC382E2CQ36537788-C8E7B91D-DBF7-40E6-B420-078F215593C3Q37000646-941BD69F-1872-4842-ADB3-8EF11619E394Q37041036-FF7B9F5F-90F4-49DB-826A-FC384F792444Q37214412-564077F6-5FD0-4E8B-ADB9-2BBCD0089D2FQ37482150-8607B201-1039-4284-BA31-931081278602Q37690880-9B222DD9-5A2C-4996-9090-11881895B8AFQ37929795-5D988B38-EF54-4C3F-95B2-139CDA1FD6ABQ39442801-D4F11F6B-F7E3-49AC-953B-E097E8180249Q42362435-1689268C-EA4E-4CCB-ADC2-019F139C12A4Q50875400-24E7C1F4-AE8C-430B-9E17-A5A43260F0D1
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Editors' Reply
@en
Editors' Reply
@nl
type
label
Editors' Reply
@en
Editors' Reply
@nl
prefLabel
Editors' Reply
@en
Editors' Reply
@nl
P3181
P1433
P1476
Editors' Reply
@en
P2093
Barbara Cohen
Gavin Yamey
P3181
P356
10.1371/JOURNAL.PMED.0020225
P407
P577
2005-07-26T00:00:00Z